Please ensure Javascript is enabled for purposes of website accessibility

Why Sesen Bio Stock Fell off a Cliff Monday

By Eric Volkman – Aug 16, 2021 at 8:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA dashes the company's hopes for its core pipeline least for now.

What happened

It's tough when any onetime highflier falls precipitously from its height. Such was the case with ambitious biotech Sesen Bio (SESN -2.00%), which saw its share price decline by a queasy 42% on Monday following continued fallout from a very discouraging communication from the FDA.

So what

A few hours short of market close on Friday, Sesen Bio announced that it received a Complete Response Letter from the healthcare regulator about its leading drug candidate, Vicineum. The FDA was the bearer of bad news, informing that company that it could not approve Vicineum "in its present form."

A researcher studying a sample in a petri dish.

Image source: Getty Images.

The regulator provided recommendations for additional data and analysis that might bolster the chances for the BLA to succeed in the future.

Sesen Bio had filed a Biologics License Application for its medication in the treatment of non-muscle-invasive bladder cancer (NMIBC) that does not initially respond to the first-line Bacillus Calmette-Guerin (BCG) therapy.

Now what

As typically happens with FDA rejections in the biotech world, Sesen Bio put a hopeful spin on the regulator's response. "We remain dedicated to our mission to save and improve the lives of patients by bringing new treatment options to patients, and we intend to work closely with the FDA to understand next steps," it quoted CEO Thomas Cannell as saying.

The company added that it aims to request a Type A meeting as soon as possible with the regulator, in order to discuss how it might increase Vicineum's chances for approval. Regardless, the FDA's decision is a stinging defeat for the company, particularly since Vicineum had performed well in late-stage clinical testing.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Sesen Bio, Inc. Stock Quote
Sesen Bio, Inc.
$0.54 (-2.00%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.